The Middle East appears in the medical literature as a high-prevalence regional setting for hepatitis C virus infection. Its importance lies not in a single clinical episode, but in the way regional prevalence shapes the number of undiagnosed infections, the burden on health systems, and the background risk encountered in patients who later develop chronic kidney disease, require hemodialysis, or enter transplantation programs.

Regional Epidemiological Profile

The estimated prevalence of hepatitis C virus infection in the general world population is about 3%, but prevalence varies markedly by geography. Western Europe is reported at approximately 0.4–3%, whereas the Middle East reaches substantially higher levels, with Egypt cited at up to 13%. Against this uneven distribution, the Middle East functions as a region where a larger proportion of the population may carry chronic infection and where the absolute number of people requiring diagnosis and follow-up is correspondingly greater.

The broader epidemiological picture is complicated by underdiagnosis. The global number of chronically infected people may exceed 170 million, while most infected individuals are unaware of their status. The same gap between infection and recognition gives regional prevalence particular practical significance: a high background rate can remain clinically silent until liver disease, renal disease, or an evaluation for transplantation brings the infection to medical attention.

Transmission and Health-System Context

Hepatitis C virus transmission is described as predominantly parenteral. Historically, blood-product transfusion, intravenous drug use, and unsafe injection procedures accounted for approximately 70% of cases in industrialized countries before the 1990s. Systematic blood screening has since reduced the residual transfusion risk to around one infection per two million transfusions, shifting attention toward current risks such as intravenous or nasal drug use, mother-to-child transmission, unsafe medical or surgical procedures, and, in selected populations, sexual transmission.

The regional setting also matters because infection risk is not determined by geography alone. Dialysis-related transmission has been estimated at around 2% per year, with major variation between countries, while health-care-associated transmission can be eradicated through strict hygiene practices. Occasional infections associated with unsafe tattooing or acupuncture remain possible, and approximately 30% of hepatitis C infections are unexplained. These routes place prevention at the intersection of individual exposure, clinical practice, and institutional infection control rather than treating prevalence as a fixed regional attribute.

Links with Kidney Disease and Dialysis

Patients infected with hepatitis C virus, including those who have kidney or liver transplants, have an increased risk of glomerular lesions leading to chronic kidney disease. In patients with membranoproliferative glomerulonephritis, hepatitis C seropositivity has been reported at roughly ten times the prevalence found among hepatitis C–negative patients. In a United States comparison of 18,002 infected patients with 25,137 controls whose baseline estimated glomerular filtration rate exceeded 60, infection was associated with a higher risk of developing chronic kidney disease stages 3–5. Decompensated liver disease predicted chronic kidney disease in both groups, but infected patients reached kidney disease sooner.

A second comparison found chronic kidney disease in 9.6% of anti-hepatitis C–positive patients versus 5.1% of negative patients; infected patients also developed chronic kidney disease and end-stage renal disease sooner, and a higher baseline viral load independently predicted chronic kidney disease. In the NHANES III analysis, hepatitis C seropositivity was associated with albuminuria in an age-dependent manner: the adjusted odds ratio was 1.84 among people aged 40–59 and 1.27 among those aged 60 or older. Among the older group, albuminuria occurred in 46% of infected individuals compared with 24% of those without hepatitis C antibodies. A Taiwanese analysis likewise found proteinuria in 8.3% of anti-hepatitis C–positive, nondiabetic patients compared with 5.1% of seronegative patients, although neither study found a consistent association with a low estimated glomerular filtration rate.

The hemodialysis population gives this regional epidemiology an additional institutional dimension. When serological tests first became available, hemodialysis patients were recognized as a high-risk group, partly because transfusions had been common and transfusion-associated hepatitis C had been frequent. Yet the correlation between infection prevalence and time on dialysis, the higher prevalence in hemodialysis than in peritoneal or home dialysis, and substantial infection among never-transfused patients also indicated ongoing nosocomial transmission within dialysis units. Improved donor screening reduced the post-transfusion risk from approximately 0.5% per blood unit in the 1980s to about 0.0001% in the United States, making failures of infection control an increasingly important explanation.

Molecular virology reinforced that conclusion. From the mid-1990s onward, phylogenetic studies identified clusters of closely related hepatitis C virus isolates among patients treated in the same hemodialysis units. A review of 20 studies found no single transmission route conclusively established after the fact, but every study implicated failures in infection-control procedures. In 18 of the 20 studies, some or all newly infected patients did not share a dialysis machine with the source patient, indicating that the internal machine circuit played, if any, only a small role. The resulting guidance does not recommend dedicated machines or patient isolation as substitutes for strict infection-control procedures; hand hygiene, gloves, disposal of single-use items, disinfection of surfaces and nondisposable equipment, waste management, and regular observational audits are emphasized instead.

Consequences for Transplantation

The prevalence of hepatitis C virus infection in the Middle East has implications beyond diagnosis because infected patients may arrive at kidney transplantation with both renal and hepatic disease. Across transplant candidates, approximately 10–25% have been found on biopsy to have advanced liver injury, including stage 3 or 4 disease. Candidates should therefore be screened for hepatitis C antibodies and, where appropriate, active viremia with nucleic acid testing. Liver biopsy remains the reference standard for assessing advanced liver disease when active infection is identified, and established or decompensated cirrhosis warrants referral for consideration of simultaneous liver–kidney transplantation.

Patients who remain on the kidney-transplant waiting list require regular monitoring for progressive liver disease, particularly where waiting times approach five to seven years. The evidence does not establish a universal consensus on treating active viremia before transplantation, although achieving a sustained virologic response before transplantation may reduce the risk of post-transplant diabetes and immune-complex glomerular disease in the allograft. These decisions are especially consequential in regions where a higher prevalence increases the number of candidates entering the transplant pathway with unrecognized or active infection.

Regional prevalence also intersects with the use of organs from hepatitis C virus–positive donors. Long-term registry and single-center experience suggests that such kidneys can be used safely in hepatitis C virus–positive recipients under agreed restrictions, generally requiring positive hepatitis C virus RNA before transplantation and prior informed consent. Donor RNA status and donor and recipient genotypes remain important limitations in the evidence base. A recipient’s preexisting infection does not reliably protect against reinfection with a different or even the same genotype, and genotype matching may reduce the risk of superinfection, although time constraints can make matching difficult.

Clinical Burden and Significance

The consequences of infection are not confined to liver histology. Among patients receiving long-term dialysis, anti-hepatitis C antibody positivity has been associated with a 1.34 adjusted relative risk of all-cause mortality. Hepatocellular carcinoma and cirrhosis occur more often as causes of death in infected patients, with an unadjusted liver-related mortality risk estimated at 5.89. Infection has also been linked to poorer mental quality of life: in a study of 165 regular dialysis patients, 83 of whom were anti-hepatitis C positive, positivity independently predicted a lower mental component score on the SF-36, although no association with the physical component score was observed.

At the same time, the disease’s course can be deceptively slow in dialysis. Available evidence suggests that hepatitis C–related liver disease may progress more slowly in dialysis patients than in patients without uremia, despite the immune compromise associated with chronic kidney failure. Hemodialysis itself appears to reduce viral load, possibly through intradialytic production of interferon-alpha, hepatocyte growth factor, or other antiviral cytokines, although the mechanism remains speculative. The Middle East therefore represents not merely a map location in hepatitis C epidemiology, but a setting where high prevalence, silent infection, renal vulnerability, dialysis transmission, transplant scarcity, and evolving antiviral and allocation policies converge.